Frazier Life Sciences Management, L.P.
Q3 2023 13F-HR Holdings
Net value change ($000)
-168,852
(-10.1%)
New positions
7
Sold out positions
4
Turnover %
21.1%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| MIRM | 91,668 | 81.3% |
| BBIO | 37,674 | 110.1% |
| RCKT | 28,748 | NEW |
| APLS | 23,358 | NEW |
| ANTX | 22,333 | NEW |
| CRNX | 21,790 | 85.5% |
| RYTM | 18,625 | 52.1% |
| SVRA | 15,120 | NEW |
| SLNO | 13,720 | NEW |
| APGE | 8,520 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| CHINOOK THERAPEUTICS, INC. | -166,956 | -100.0% |
| SNDX | -68,914 | -88.8% |
| PHAT | -39,932 | -27.6% |
| ARQT | -36,648 | -44.3% |
| HilleVax, Inc. | -36,583 | -21.8% |
| NAMS | -17,048 | -13.2% |
| MORPHIC HLDG INC | -15,222 | -100.0% |
| Theseus Pharmaceuticals, Inc. | -14,928 | -71.2% |
| VRNA | -13,110 | -21.1% |
| REATA PHARMACEUTICALS INC | -10,240 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
1,566
(0.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|